Table 2 β₁-receptor agonists

Species

Rat, dog

Cat, dog,

Rat, dog, rabbit, guinea pig

Dog, pig, rabbit, guinea pig

Dog, pig

Dosage (in vivo)

0.4 μg/kg/min – 4.2 μg/kg/min

0.2 μg/kg/min – 5.0 μg/kg/min

5.7 ng/kg/min – 1 μg/kg (bolus)

2.0 μg/kg/min – 30 μg/kg/min

2.0 μg/kg/min – 30 μg/kg/min

Administration

i.v. (in vivo studies), Retrograd coronary perfusion (in vitro studies)

i.v. (in vivo studies)

i.v. (in vivo studies), Retrograd coronary perfusion or in preparation solution (in vitro studies)

i.v. (in vivo studies), Retrograd coronary perfusion or in preparation solution (in vitro studies)

i.v. (in vivo studies)

Target temperature

12 °C–28 °C

28 °C–30 °C

20 °C–28 °C

22 °C–31 °C

25 °C–30 °C

Cardiac effect (hypothermia)

Elevated CO (low dose) [27, 34, 38]. Depressed CO (high dose) [21, 27, 34, 35, 37].

Negative inotropic effects (in vitro) [41, 42].

Increased contractile force [26, 45]. Depressed CO [40].

No effect on CO [50, 51]. Negative or depressed inotropic effect (in vitro) [52, 53].

Positive inotropic effects (in vitro) [22, 24, 54].

Elevated CO [38, 57]. Increased contraction velocity (in vitro) [24].

Reduced or depressed inotropic effect (in vitro) [56].

Elevated CO or positive inotropic effects [57, 61, 63].

No effect on CO [62, 63].